CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed Inc.

Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies fully enrolled; topline data expected December 2024.
KOL event on July 23, 2024 features John-Paul Taylor (Newcastle Univ.) and Ralph A. Nixon (NYU Grossman School of Medicine).
Agenda includes DLB disease state, neflamapimod mechanism, plasma phosphorylated tau patient selection, and trial design.
Live Q&A session moderated by CervoMed CEO John Alam following the formal presentations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.